1. Home
  2. JVA vs NEUP Comparison

JVA vs NEUP Comparison

Compare JVA & NEUP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Coffee Holding Co. Inc.

JVA

Coffee Holding Co. Inc.

SELL

Current Price

$4.63

Market Cap

26.4M

ML Signal

SELL

Logo Neuphoria Therapeutics Inc.

NEUP

Neuphoria Therapeutics Inc.

SELL

Current Price

$3.32

Market Cap

18.5M

Sector

N/A

ML Signal

SELL

Company Overview

Basic Information
Metric
JVA
NEUP
Founded
1971
1996
Country
United States
United States
Employees
92
N/A
Industry
Packaged Foods
Sector
Consumer Staples
Exchange
Nasdaq
Nasdaq
Market Cap
26.4M
18.5M
IPO Year
1997
2002

Fundamental Metrics

Financial Performance
Metric
JVA
NEUP
Price
$4.63
$3.32
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
★ 76.6K
11.6K
Earning Date
09-11-2026
11-13-2026
Dividend Yield
★ 1.73%
N/A
EPS Growth
★ N/A
N/A
EPS
★ 0.68
N/A
Revenue
★ $90,655,294.00
$1,174,165.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$6.81
★ N/A
Revenue Growth
★ 17.54
N/A
52 Week Low
$2.93
$3.19
52 Week High
$5.03
$17.90

Technical Indicators

Market Signals
Indicator
JVA
NEUP
Relative Strength Index (RSI) 67.92 20.00
Support Level $4.15 $3.28
Resistance Level $4.59 $3.86
Average True Range (ATR) 0.18 0.07
MACD 0.05 -0.02
Stochastic Oscillator 79.16 4.60

Price Performance

Historical Comparison
JVA
NEUP

About JVA Coffee Holding Co. Inc.

Coffee Holding Co Inc is engaged in wholesale coffee operations, including manufacturing, roasting, packaging, marketing, and distributing roasted and blended coffees for privately labeled accounts and its brands, and it sells green coffee. The Company also manufactures and sells coffee roasters. Its products include wholesale green coffee, private-label coffee, and branded coffee. The company sells its coffee products throughout the United States, Canada, and certain Asian countries. The group's services are Custom Blending, Food Service Programs, and Private Label Services.

About NEUP Neuphoria Therapeutics Inc.

Neuphoria Therapeutics Inc is a clinical-stage biotechnology company focused on therapies for serious central nervous system disorders. Its lead product candidate, BNC210, is an oral, proprietary, selective negative allosteric modulator of the alpha7 nicotinic acetylcholine receptor. The company has discontinued development of BNC210 for social anxiety disorder, while its BNC210 program for post-traumatic stress disorder is currently paused and no active clinical trial is underway. The company operates through a single operating and reporting segment focused on the discovery and development of allosteric ion-channel modulators for serious CNS disorders with high unmet medical need.

Share on Social Networks: